Biotech: Page


  • A sign reads "AstraZeneca" with the company logo on an all-glass-grided building facade.
    Image attribution tooltip
    Alamy
    Image attribution tooltip

    New data could widen use of AstraZeneca, Amgen immune disease drug

    Tezspire succeeded in a study in eosinophilic esophagitis, which could become the drug’s third approved indication and unlock what’s viewed as a blockbuster opportunity.

    By • Aug. 27, 2026
  • A photo of the packaging for the pancreatic cancer drug Rasonque
    Image attribution tooltip
    Retrieved from Revolution Medicines.
    Image attribution tooltip

    Revolution pancreatic cancer drug should quickly become a blockbuster, analysts say

    Rasonque’s $39,800 monthly list price surpassed Wall Street forecasts and led to rosier sales projections ahead of what one analyst described as a “historic” launch.

    By Kristin Jensen • Aug. 27, 2026
  • Explore the Trendline➔
    Image attribution tooltip
    Spencer Platt via Getty Images
    Image attribution tooltip
    Trendline

    Emerging biotech

    New biotechs continue to emerge despite a challenging market environment that has forced venture firms to build their drug startups more cautiously.

    By BioPharma Dive staff
  • A sign at the Revolution Medicines campus.
    Image attribution tooltip
    Courtesy of Revolution Medicines
    Image attribution tooltip

    Revolution drug heralded as a pancreatic cancer breakthrough cleared by FDA

    Rasonque’s speedy approval — just a month after a completed submission — represents a paradigm shift for a notoriously deadly cancer and begins what analysts see as a highly lucrative drug launch.

    By • Updated Aug. 27, 2026
  • A photo of Biohaven CEO Vlad Coric
    Image attribution tooltip
    Courtesy of Biohaven Ltd.
    Image attribution tooltip

    Biohaven trades cash for ‘upside’ with $795M epilepsy drug deal

    Faced with a dwindling bank account after a series of research setbacks, Biohaven is letting go of its most advanced experimental drug in a deal one analyst viewed as a “surprising” transaction.

    By Kristin Jensen • Aug. 26, 2026
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Zepbound may cut healthcare costs, study says; Summit, Akeso drug hits in another China trial

    A real-world study suggests Zepbound use could reduce the rates of hospital stays and ER visits. Elsewhere, McKesson sprung for a multibillion-dollar deal and J&J nabbed a noteworthy approval.

    By BioPharma Dive staff • Aug. 26, 2026
  • Cancer cells
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    New Jazz cancer drug approval could drive blockbuster sales

    Ziihera can now be used as an initial treatment for all HER2-positive gastroesophageal adenocarcinomas, dramatically expanding the drug’s market potential.

    By • Aug. 25, 2026
  • Female Doctor Analyzing Medical Data
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Emerging biotech

    Will a ‘reset’ reignite investment in women’s health startups?

    After peaking in 2024, venture investments in startups involved in the space declined last year. But a broader adoption of AI and a widening definition of what constitutes women’s health could spur a rebound, some say.

    By • Aug. 25, 2026
  • A building is seen through a fence.
    Image attribution tooltip

    Karissa Waddick/Industry Dive

    Image attribution tooltip
    Emerging biotech

    Young startups miss out on biotech venture funding rebound, MassBio says

    A new report found that the sizes of seed rounds and Series A financings for Massachusetts biotech startups are going in opposite directions, as funding slows for young companies with the “riskiest science.”

    By • Aug. 25, 2026
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    FDA extends review of Capricor cell therapy; Pain drug startup to go public

    The agency is now reviewing an updated application for deramiocel with a “refined” indication. Elsewhere, a startup co-founded by Vivek Ramaswamy is taking a speedy path to the public markets.

    By • Aug. 24, 2026
  • Two people in business suits stand next to a closed manufacturing pod emblazoned with the word Cellares.
    Image attribution tooltip
    Permission granted by Cellares
    Image attribution tooltip
    Emerging biotech

    Cellares, a cell therapy manufacturing specialist, to lay off 100 employees

    The restructuring comes after an unnamed "large pharmaceutical customer" terminated a contract with the company, Cellares CEO Fabian Gerlinghaus posted on LinkedIn.

    By • Aug. 24, 2026
  • A sign with the Roche logo stands in front of a tall building.
    Image attribution tooltip
    Permission granted by Roche
    Image attribution tooltip
    Obesity drugs

    Roche commits to lean-mass preservation with Hanmi obesity deal

    For $190 million up front and as much as $2.3 billion overall, the Swiss drugmaker is building its portfolio with a shot that aims to spur weight loss but spare muscle tissue.

    By • Aug. 24, 2026
  • Doctor wearing lab coat using laptop
    Image attribution tooltip
    hirun via Getty Images
    Image attribution tooltip
    Sponsored by PharmaForceIQ

    Pharma marketers need a share-of-answer strategy before AI spend

    AI is changing how HCPs seek answers. Pharma marketers need a new strategy.

    Aug. 24, 2026
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Shareholder pressures Capricor; Lilly dives deeper into vaccines

    Kaos Capital wants a “governance reset” to alter the Duchenne cell therapy maker’s strategic course. Elsewhere, Bristol Myers furthered efforts to build an “AI-powered” discovery engine.

    By BioPharma Dive staff • Aug. 21, 2026
  • A picture of a Moderna building.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Vaccines

    Cancer vaccine win restores Wall Street’s faith in Moderna

    Moderna gained $45 billion in market value in a single day, a surge that brought the company’s stock to levels not seen since 2024 — and saddled it with expectations that may be tough to meet. 

    By , • Aug. 20, 2026
  • An illustration of immune cells attacking a tumor.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Moderna and Merck cancer vaccine returns ‘landmark’ result in melanoma

    At an interim data check, investigators of a key trial found the individualized mRNA treatment kept disease from returning and stopped its spread, sparking a surge in Moderna shares.

    By • Aug. 19, 2026
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    AstraZeneca scores in lung cancer; Sandoz inks a China deal

    A combination of AstraZeneca’s Tagrisso and Hutchmed’s Orpathys extended survival for some lung cancer patients. Elsewhere, MapLight floated the idea of partnering on its autism drug.

    By BioPharma Dive staff • Aug. 18, 2026
  • The logo of Amylyx Pharmaceuticals is seen through an office window.
    Image attribution tooltip
    Permission granted by Amylyx Pharmaceuticals
    Image attribution tooltip

    Amylyx’s bet on a GLP-1 blocker pays off

    A late-stage trial found the drug, which Amylyx bought for cheap in a bankruptcy auction, was effective at regulating blood sugar in patients who’d just undergone bariatric surgery.

    By • Aug. 18, 2026
  • Illustration of a lipid nanoparticle carrying messenger RNA into a human cell, the biotech behind Moderna's game-changing flu vax
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Vaccines

    FDA nod is just the first hurdle for Moderna’s potential blockbuster flu vax

    Strain selection timing and mRNA skepticism could limit the impact of Moderna’s game-changing mRNA flu shot.

    By Alexandra Pecci • Aug. 17, 2026
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Capricor shares spike on CEO comments; Cytokinetics sues Bristol Myers

    The FDA is “willing to review” an updated submission for Capricor’s Duchenne cell therapy, its CEO said. Elsewhere, a heart drug battle spilled into court and Rigel priced the first “Protac” medicine.

    By BioPharma Dive staff • Aug. 14, 2026
  • As pharma manufacturing investment skyrockets, investments have poured into regional biotech hubs eager from NY to Kansas City
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Biotech initiatives pick up as more regions race to become hubs

    New government funding from Pennsylvania to Kansas City is strengthening biotech hubs — but experts say money alone won’t determine where pharma builds next.

    By Alexandra Pecci • Aug. 14, 2026
  • Illustration of lung cancer
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    New Taiho, Cullinan data heats up lung cancer drug battle

    The findings position their drug, zipalertinib, as a threat to multiple approved medicines — while setting a bar for others in testing.

    By • Aug. 13, 2026
  • Formation Bio has tapped Biogen and Pfizer vet Mike Ehlers to be its new R&D chief
    Image attribution tooltip
    Permission granted by Image courtesy of Formation Bio
    Image attribution tooltip
    Profile

    Formation Bio taps Biogen, Pfizer alum to tackle R&D’s ‘boring middle’

    Michael Ehlers bets AI can ease the clinical-development bottleneck — but scaling Formation Bio’s pipeline will also require human judgment.

    By Alexandra Pecci • Aug. 12, 2026
  • psychedelic brain
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Brain drug revival

    Psychedelics developer Definium scores more positive data for LSD pill

    Results from a late-stage study focused on generalized anxiety disorder were a “clean win” to analysts, who believe Definium has a drug with multibillion-dollar sales potential.

    By • Aug. 12, 2026
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Silence cashes in on ‘differentiated’ data; UK reaffirms support for childhood vaccines

    Some analysts believe Silence’s polycythemia vera drug could be superior to a closely watched Takeda medicine. Elsewhere, the FDA spurned a radiopharmaceutical and AbCellera shares climbed to levels not seen since 2023.

    By BioPharma Dive staff • Aug. 12, 2026
  • An illustration of lymphocytes
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Immune reset

    Boulevard starts up with $65M to pursue targeted autoimmune drugs

    Co-founded by pioneering researcher Georg Schett and ex-Sanofi CSO Frank Nestle, the startup is advancing a trio of multifaceted antibodies with the potential to treat several immune diseases.

    By • Aug. 12, 2026